Coronavirus disease 2019 (COVID-19) and autoimmunity
The coronavirus 2019 pandemic (coronavirus disease, COVID-19), etiologically related to the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2), has once again reawakened healthcare professionals’ interest towards new clinical and conceptual issues of human immunology and immunopathol...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2021-03-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2986 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839568247297409024 |
|---|---|
| author | E. L. Nasonov |
| author_facet | E. L. Nasonov |
| author_sort | E. L. Nasonov |
| collection | DOAJ |
| description | The coronavirus 2019 pandemic (coronavirus disease, COVID-19), etiologically related to the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2), has once again reawakened healthcare professionals’ interest towards new clinical and conceptual issues of human immunology and immunopathology. An unprecedented number of clinical trials and fundamental studies of epidemiology, virology, immunology and molecular biology, of the COVID-19 clinical course polymorphism and pharmacotherapy have been conducted within one year since the outbreak of 2019 pandemic, bringing together scientists of almost all biological and physicians of almost all medical specialties. Their joint efforts have resulted in elaboration of several types of vaccines against SARS-CoV-2 infection and, in general, fashioning of more rational approaches to patient management. Also important for COVID-19 management were all clinical trials of biologics and “targeted” anti-inflammatory drugs modulating intracellular cytokine signaling, which have been specifically developed for treatment immune-mediated inflammatory rheumatic disease (IMIRDs) over the past 20 years. It became obvious after a comprehensive analysis of the entire spectrum of clinical manifestations and immunopathological disorders in COVID-19 is accompanied by a wide range of extrapulmonary clinical and laboratory disorders, some of which are characteristic of IMIRDs and other autoimmune and auto-in-flammatory human diseases. All these phenomena substantiated the practice of anti-inflammatory drugs repurposing with off-label use of specific antirheumatic agents for treatment of COVID-19. This paper discusses potential use of glucocorticoids, biologics, JAK inhibitors, etc., blocking the effects of pro-inflammatory cytokines for treatment of COVID-19. |
| format | Article |
| id | doaj-art-a12dbb6954a744da89cff16d1036c8b2 |
| institution | Matheson Library |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2021-03-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-a12dbb6954a744da89cff16d1036c8b22025-08-04T17:04:00ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922021-03-0159153010.47360/1995-4484-2021-5-302677Coronavirus disease 2019 (COVID-19) and autoimmunityE. L. Nasonov0V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)The coronavirus 2019 pandemic (coronavirus disease, COVID-19), etiologically related to the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2), has once again reawakened healthcare professionals’ interest towards new clinical and conceptual issues of human immunology and immunopathology. An unprecedented number of clinical trials and fundamental studies of epidemiology, virology, immunology and molecular biology, of the COVID-19 clinical course polymorphism and pharmacotherapy have been conducted within one year since the outbreak of 2019 pandemic, bringing together scientists of almost all biological and physicians of almost all medical specialties. Their joint efforts have resulted in elaboration of several types of vaccines against SARS-CoV-2 infection and, in general, fashioning of more rational approaches to patient management. Also important for COVID-19 management were all clinical trials of biologics and “targeted” anti-inflammatory drugs modulating intracellular cytokine signaling, which have been specifically developed for treatment immune-mediated inflammatory rheumatic disease (IMIRDs) over the past 20 years. It became obvious after a comprehensive analysis of the entire spectrum of clinical manifestations and immunopathological disorders in COVID-19 is accompanied by a wide range of extrapulmonary clinical and laboratory disorders, some of which are characteristic of IMIRDs and other autoimmune and auto-in-flammatory human diseases. All these phenomena substantiated the practice of anti-inflammatory drugs repurposing with off-label use of specific antirheumatic agents for treatment of COVID-19. This paper discusses potential use of glucocorticoids, biologics, JAK inhibitors, etc., blocking the effects of pro-inflammatory cytokines for treatment of COVID-19.https://rsp.mediar-press.net/rsp/article/view/2986covid-19immune-mediated inflammatory rheumatic diseasesautoimmunityglucocorticoidsbiologics |
| spellingShingle | E. L. Nasonov Coronavirus disease 2019 (COVID-19) and autoimmunity Научно-практическая ревматология covid-19 immune-mediated inflammatory rheumatic diseases autoimmunity glucocorticoids biologics |
| title | Coronavirus disease 2019 (COVID-19) and autoimmunity |
| title_full | Coronavirus disease 2019 (COVID-19) and autoimmunity |
| title_fullStr | Coronavirus disease 2019 (COVID-19) and autoimmunity |
| title_full_unstemmed | Coronavirus disease 2019 (COVID-19) and autoimmunity |
| title_short | Coronavirus disease 2019 (COVID-19) and autoimmunity |
| title_sort | coronavirus disease 2019 covid 19 and autoimmunity |
| topic | covid-19 immune-mediated inflammatory rheumatic diseases autoimmunity glucocorticoids biologics |
| url | https://rsp.mediar-press.net/rsp/article/view/2986 |
| work_keys_str_mv | AT elnasonov coronavirusdisease2019covid19andautoimmunity |